目的骨化三醇联用缬沙坦对减少2型糖尿病肾病患者蛋白尿的有效性与安全性评估。方法选取62例住院及门诊2型糖尿病肾病患者，随机分为骨化三醇组（VD3），缬沙坦组(ARB)，和联合治疗组(ARB+VD3)，观察8w，测定患者治疗前后尿蛋白，肾功能，血钙。结果治疗后ARB组尿蛋白，VD3组尿蛋白较基线下降（P<0.05）,联合治疗组尿蛋白较基线明显下降（P<0.01）,较之ARB组及 VD3组其下降更为明显，差异有统计学意义（均P<0.05）。所有患者均无明显不良反应，未发生高钙血症。结论骨化三醇联合缬沙坦可以有效降低糖尿病肾病患者的蛋白尿，保护肾功能，疗效优于单独用药。“,”Objective To assess the effectiveness and safety of calcitriol combined with Valsartan in the treatment of type 2 diabetic kidney disease . Methods We conducted a randomized controlled trial, by which 62 patients with type 2 diabetic kidney disease were randomly assigned to calcitriol group (VD3),Valsartan group (ARB)or combined treatment group (ARB+VD3). The end points were assessed at 8 weeks, including 24-hour urinary protein, renal function and blood calcium.Results At 8 weeks after treatment, 24-hour urinary protein levels were significantly reduced in each group, compared with that before treatment (P<0.05).24-hour urinary protein level in combined treatment was significantly lower than that in calcitriol group and valsartan group (P<0.05). No side effects such as hypercalcemia were observed in all patients. Conclusion combined treatment with calcitriol and valsartan can effectively alleviate proteinuria and protect renal function.